You are not logged in.

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

Dodson, P. M., Haynes, J., Starczynski, J., Farmer, J., Shigdar, S., Fegan, G., Johnson, R.J. and Fegan, C. 2003, The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion, Eye, vol. 17, no. 6, pp. 772-777, doi: 10.1038/sj.eye.6700452.

Attached Files
Name Description MIMEType Size Downloads

Title The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion
Author(s) Dodson, P. M.
Haynes, J.
Starczynski, J.
Farmer, J.
Shigdar, S.ORCID iD for Shigdar, S.
Fegan, G.
Johnson, R.J.
Fegan, C.
Journal name Eye
Volume number 17
Issue number 6
Start page 772
End page 777
Total pages 6
Publisher Nature Publishing Group
Place of publication London, England
Publication date 2003
ISSN 0950-222X
Summary Retinal vein occlusion (RVO) is associated with hyperhomocysteinaemia and the antiphospholipid syndrome—disorders known to contribute to both arterial and venous thrombosis. In both of these conditions and RVO, platelet activation occurs. Aspirin, not warfarin, is the most effective antithrombotic agent in RVO and, taken together, these observations suggest an important role for platelets in this common ocular thrombotic condition. Platelet glycoprotein Ia/IIa (GpIa/IIa) is an adhesion molecule mediating platelet–collagen interactions and is key to the initiation of thrombosis. Recently, the cellular density of this molecule was shown to be determined by two silent, linked polymorphisms (C807T/G873A) within the GpIa/IIa gene. There is evidence that some of the resulting genotypes are associated with thrombo-embolic disease. This study therefore aimed to establish the prevalence of the GpIa/IIa polymorphisms and the three commonest hereditary thrombophilic disorders (prothrombin gene G20210A (PT) mutation, Factor V Leiden (FVL), and the thermolabile methylene tetrahydrofolate reductase C677T (MTHFR) mutation) in patients with RVO and normal controls. The GpIa/IIa polymorphisms and thrombophilic abnormalities were all identified using the polymerase chain reaction.

Our results show that the frequency of the GpIa/IIa polymorphisms was similar in our normal control population to previously published series. Patients with RVO, however, had only a 10% (4/40) frequency of the lowest risk subtype (CC/GG) compared to 37.5% (15/40) in the control group—P 0.0039. The incidence of the PT, FVL, and MTHFR thrombophilic mutations was not different between the two groups, but interestingly none of the 7/40 RVO cases with a PT, FVL, or MTHFR mutation had the low-risk GpIa/IIa genotype while all but one of the controls did—P<0.05. Thus, 17.5% of RVO patients harboured more than one prothrombotic abnormality. The principal difference between the RVO and control group was the very high incidence of the intermediate-risk GpIa/IIa subtype (CT/GA)—82.5 vs 50%, P<0.05.

These results suggest a major role for GpIa/IIa polymorphisms in the pathogenesis of RVO.
Language eng
DOI 10.1038/sj.eye.6700452
Field of Research 110201 Cardiology (incl Cardiovascular Diseases)
110202 Haematology
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2003, Nature Publishing Group
Persistent URL

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 17 times in TR Web of Science
Scopus Citation Count Cited 24 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 718 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 01 Apr 2010, 16:30:40 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact